

## **Workshop "Clinical introduction and evaluation of new anticancer drugs"**

**Organised with Department of Drug Management and Informatics  
in Stockholm County Council**

**March 11, 2009  
09.00 – 16.30**

**Venue: The Conference room, Cancer Center Karolinska (CCK), Karolinska University  
Hospital, Solna, Stockholm, Building: R:8 5<sup>th</sup> floor**

The development of new anti tumour agents is continuously increasing. There are important possibilities to improve survival of cancer patients. At the same time increasing costs cause frustration among payers. We need the knowledge to be able to optimise drug treatment. With this background OEI together with the Department of Drug Management and Informatics in Stockholm County Council arrange this workshop.

*The following questions will be discussed:*

- Variable uptake on new anti cancer agents: consequences for patients, health care costs and industrial production
- Future development – more new targets, new pharmaceuticals, increased specificity of action
- Information on new pharmaceuticals – horizon scanning
- A structure for implementation and evaluation of new anti tumour agents in clinical practise
- Optimal use of anti tumour agents – Biomarkers for prediction of response, pharmacogenetics/genomics and molecular imaging as tools for individualized treatment
- What is the significant clinical effect of pharmacological anticancer treatment from the payer's perspective?
- The patient's perspective
- The role of the pharmaceutical industry and IMI;
- How to collaborate to move towards optimal use of anticancer drugs: -"The right treatment to the right patient at the right time";

The speakers are recruited from OEI's centres and Department of Drug Management and Informatics in Stockholm County Council.

On behalf of OEI president, Marco Pierotti, I have the privilege to welcome you to Stockholm.

Ulrik Ringborg

Former president of OEI  
Director of Cancer Center Karolinska